GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Cyclically Adjusted Price-to-FCF

iX Biopharma (SGX:42C) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


iX Biopharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for iX Biopharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Cyclically Adjusted Price-to-FCF Chart

iX Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

iX Biopharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of iX Biopharma's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iX Biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where iX Biopharma's Cyclically Adjusted Price-to-FCF falls into.



iX Biopharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

iX Biopharma's Cyclically Adjusted FCF per Share for the fiscal year that ended in Jun23 is calculated as:

For example, iX Biopharma's adjusted Free Cash Flow per Share data for the fiscal year that ended in Jun23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun23 (Change)*Current CPI (Jun23)
=-0.011/128.7287*128.7287
=-0.011

Current CPI (Jun23) = 128.7287.

iX Biopharma Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.005 100.560 -0.006
201506 -0.013 100.684 -0.017
201606 -0.017 101.688 -0.022
201706 -0.008 103.349 -0.010
201806 -0.015 106.317 -0.018
201906 -0.024 108.070 -0.029
202006 -0.014 108.767 -0.017
202106 -0.013 114.631 -0.015
202206 0.004 125.017 0.004
202306 -0.011 128.729 -0.011

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


iX Biopharma  (SGX:42C) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


iX Biopharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


iX Biopharma (SGX:42C) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma (SGX:42C) Headlines

No Headlines